-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

905A.O1.6 905. Outcomes Research – Lymphoid Malignancies: Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma

Symposia: Outcomes Research—Lymphoid Malignancies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, Plasma Cell Disorders, health disparities research, Diversity, Equity, and Inclusion (DEI) , patient-reported outcomes, Diseases, real-world evidence, Lymphoid Malignancies, Adverse Events, survivorship
Monday, December 11, 2023: 4:30 PM-6:00 PM
Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
Moderators:
Shonali Midha, MD, BS, Dana-Farber Cancer Institute and Mazie Tsang, MD, UCSF
Disclosures:
Midha: Abbvie: Current holder of stock options in a privately-held company; Pfizer: Consultancy. Tsang: Poseida Therapeutics: Current holder of stock options in a privately-held company; Novartis: Consultancy.
In this session we will try to understand the balance between efficacy, safety and tolerability, and the importance of quality of life and patient-reported outcome measurement (PROM) in patients with multiple myeloma according different treatment strategies. 
4:30 PM

Roberto Mina, MD1*, Anne K Mylin2*, Hisayuki Yokoyama3*, Hila Magen4*, Winfried Alsdorf5*, Monique C Minnema6*, Leyla Shune, MD7, Iris Isufi8, Simon J. Harrison, MBBS, MRCP, FRCPath, FRACP, PhD9,10,11, Urvi A Shah, MD12, Jordan M. Schecter13, Nikoletta Lendvai13*, Katharine S Gries14*, Eva G Katz14*, Ana Slaughter15*, Carolina Lonardi16*, Jane Gilbert17*, Quanlin Li18*, William Deraedt19*, Octavio Costa Filho20*, Nitin Patel20*, Lionel Karlin21* and Katja Weisel, MD5

1Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
2Department of Hematology, Rigshospitalet, Copenhagen, Denmark
3Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan
4Chaim Sheba Medical Center, Ramat-Gan, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, ISR
5University Medical Center Hamburg-Eppendorf, Hamburg, Germany
6University Medical Center Utrecht, Utrecht, Netherlands
7University of Kansas Medical Center, Kansas City, KS
8Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT
9Peter MacCallum Cancer Centre, Melbourne, Australia
10Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
11Royal Melbourne Hospital, Melbourne, Australia
12Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
13Janssen Research & Development, Raritan, NJ
14Janssen Global Services, LLC, Raritan, NJ
15Cilag GmbH International, Zug, Switzerland
16Janssen, Buenos Aires, ARG
17Janssen Research & Development, High Wycombe, United Kingdom
18Janssen Research & Development, Apex, NC
19Janssen Research & Development, Beerse, Belgium
20Legend Biotech USA Inc., Somerset, NJ
21Centre Hospitalier Lyon Sud, Pierre-Bénite, France

4:45 PM

David M. Cordas dos Santos, MD1,2,3*, Tobias Tix, MD4* and Kai Rejeski, MD4,5

1Department of Oncology, Dana-Farber Cancer Institute, Boston, MA
2Harvard Medical School, Boston, MA
3Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA
4Department of Medicine III, LMU University Hospital, Munich, Germany
5German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany

5:00 PM

Shakira J. Grant, MBBS, MSCR1, Milenka Jean-Baptiste, MPH2*, Jiona A Mills, BS, MPH3*, Shanghong Wang, BA2* and Paul Mihas, MA4*

1U.S. House of Representatives, Ways and Means Subcommittee on Health, ASH/AAAS Science and Policy Fellow, Washington, DC
2Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
3Center for Aging and Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
4Odum Institute For Research In Social Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC

5:15 PM

Rahul Banerjee, MD1,2, Rachael Sexton, MS3*, Andrew J. Cowan, MD1,2, Sikander Ailawadhi4, S. Vincent Rajkumar, MD5, Shaji Kunnathu Kumar, MD6, Sagar Lonial, MD7*, Bart Barlogie, MD8*, Brian GM Durie, MD9, Saad Z Usmani, MD10, Antje Hoering, PhD3 and Robert Z. Orlowski, MD, PhD11

1Fred Hutchinson Cancer Center, Seattle, WA
2University of Washington, Seattle, WA
3Cancer Research And Biostatistics, Seattle, WA
4Mayo Clinic Florida, Jacksonville, FL
5Mayo Clinic, Rochester, MN
6Division of Hematology, Mayo Clinic, Rochester, MN
7Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA
8University of Arkansas for Medical Sciences, Little Rock, AR
9International Myeloma Foundation, Studio City, CA
10Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
11The University of Texas MD Anderson Cancer Center, Houston, TX

5:30 PM

Francesco Marchesi1*, Jon Salmanton-García, PhD2*, Francesca Farina3*, Barbora Weinbergerova4*, Federico Itri5*, Julio Dávila-Valls6*, Sonia Martín-Pérez7*, Andreas Glenthoej, MD, PhD8,9, Ditte Hersby, MD10*, Maria Gomes Da Silva11*, Raquel Nunes-Rodrigues12*, Raul Cordoba, MD, PhD13, Alberto Lopez Garcia, MD13, Ziad Emarah14*, Shaimaa El-Ashwah, MD15*, Yavuz M. Bilgin, MD PhD16*, Laman Rahimli17*, Oliver Cornely18* and Livio Pagano, MD19*

1Hematology Unit, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (I.F.O.), Rome, ITA
2University Hospital of Cologne, Cologne, Ghana
3IRCCS Ospedale San Raffaele, Milano, Italy
4FN Brno, Brno, CZE
5San Luigi Gonzaga Hospital - Orbassano, Orbassano, Italy, Orbassano, ITA
6Hospital Universitario Nuestra Senora de Sonsoles, Avila, ESP
7Hospital Nuestra Senora de Sonsoles, -, ESP
8Herlev University Hospital, Hellerup, Denmark
9Danish Red Blood Cell Center, Department of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
10Rigshospitalet, 2100, AL, DNK
11Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, PRT
12Departamento De Hematologia, Instituto PortuguêS De Oncologia, Lisboa, Po, Lisbon, PRT
13Fundacion Jimenez Diaz University Hospital, Madrid, Spain
14Oncology Center, Mansoura University, Mansoura, Egypt, -, EGY
15Oncology Center, Mansoura University Faculty of Medicine, Mansoura, Egypt
16Department of Internal Medicine, Adrz, Goes, Netherlands
17Uniklinik Köln, -, DEU
18Uniklinik köln, Cologne, AL, DEU
19Università Cattolica del Sacro Cuore, Roma, Italy

5:45 PM

Ghulam Rehman Mohyuddin, MD1, Samuel M Rubinstein, MD, MS2*, Shaji Kunnathu Kumar, MD3, S. Vincent Rajkumar, MD4, Rafael Fonseca, MD5, Nadine Abdallah, MD4, Greg Calip6*, Xiaoyan Wang7*, Christina Parrinello7* and Doug Sborov8

1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
2Lineberger Comprehensive Cancer Center, Chapel Hill, NC
3Division of Hematology, Mayo Clinic, Rochester, MN
4Mayo Clinic, Rochester, MN
5Mayo Clinic, Phoenix, AZ
6Flatiron Health, New York City, NY
7Flatiron Health, New York City
8University of Utah, Huntsman Cancer Institute, Salt Lake Cty, UT

*signifies non-member of ASH